Bayer Opens Innovation Center in China, Signaling Long-Term Commitment
BEIJING (CHINA) – Bayer, a leading global healthcare and agribusiness company, has launched its first innovation center in China, the Bayer E-Town Open Innovation Center in Beijing. This opening marks a critically important step in Bayer’s “in China, for Global” strategy, aiming to foster local biopharmaceutical innovation and accelerate the progress and globalization of new medicines.
The center will function as a hub for incubating promising Chinese biopharmaceutical companies, facilitating collaboration with top academic and clinical research institutions, and connecting local innovation with Bayer’s global R&D network.
“This innovation center is a true milestone in our long-term commitment to China,” stated Anastasia Hager, Senior Vice President of R&D and Head of Drug Finding Sciences at Bayer Pharmaceuticals. “We recognize China as a resilient and vital innovation engine, integral to our global strategy. The center will accelerate the thriving innovation ecosystem in Beijing and Greater China while serving as a bridge to our worldwide research and development efforts.”
Hager emphasized China’s growing strength in connecting academia, startups, and hospitals, alongside advancements in data science and artificial intelligence. These capabilities will enable Bayer to conduct more efficient clinical trials and deliver medicines to patients faster.
The initiative is also supported by the Chinese government’s commitment to attracting foreign investment and its new policies allowing foreign companies to participate in the research and development of cutting-edge therapies like gene and cell therapies, creating opportunities for collaborative innovation.
During his first visit to China, hager expressed optimism about the country’s progress, noting a “real commitment and pragmatism.” He believes China’s continued openness is cultivating a dynamic surroundings, making it the right choice for bayer to strengthen its presence and forge partnerships.He concluded that China is rapidly becoming a key player in the global pharmaceutical landscape,and a strong presence there is essential for driving global scientific progress.
